Description
| - Compds. of formula I [R1 = aryl, heteroaryl, arylalkyl, heteroarylalkyl, diphenylalkyl, etc.; R2, R3 = H, OH, alkoxy, alkyl, cycloalkyl, etc.; R4, R5, R7, R8 = H, substituted OH, substituted amino, alkyl, aryl, cycloalkyl, etc.; R6 = acyl, substituted sulfonyl; R9, R10 = H, F, CF3, alkyl, cycloalkyl, arylalkyl, etc.; X, Z = C, N] are prepd. which are useful as inhibitors of Type 3 17.beta.-Hydroxysteroid Dehydrogenase. Also disclosed are pharmaceutical compns. contg. said compds. and their use for the treatment or prevention of androgen dependent diseases. Thus, II was prepd. in several steps. The prepd. compds. had type 3 17.beta.-hydroxysteroid dehydrogenase binding activity of 0.010 to 100 nM.
- Compds. of formula I [R1 = aryl, heteroaryl, arylalkyl, heteroarylalkyl, diphenylalkyl, etc.; R2, R3 = H, OH, alkoxy, alkyl, cycloalkyl, etc.; R4, R5, R7, R8 = H, substituted OH, substituted amino, alkyl, aryl, cycloalkyl, etc.; R6 = acyl, substituted sulfonyl; R9, R10 = H, F, CF3, alkyl, cycloalkyl, arylalkyl, etc.; X, Z = C, N] are prepd. which are useful as inhibitors of Type 3 17.beta.-Hydroxysteroid Dehydrogenase. Also disclosed are pharmaceutical compns. contg. said compds. and their use for the treatment or prevention of androgen dependent diseases. Thus, II was prepd. in several steps. The prepd. compds. had type 3 17.beta.-hydroxysteroid dehydrogenase binding activity of 0.010 to 100 nM. (en)
|